

INTRABIOTICS PHARMACEUTICALS INC /DE

Form 8-K

September 23, 2003

Table of Contents

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 19, 2003

IntraBiotics Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

0-29993

(Commission File No.)

94-3200380

(IRS Employer Identification No.)

2483 East Bayshore Road, Suite 100

Palo Alto, California 94303

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(650) 526-6800**

TABLE OF CONTENTS

Item 5. Other Events and Regulation FD Disclosure

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits

SIGNATURE

INDEX TO EXHIBITS

EXHIBIT 99.1

Table of Contents

Item 5. Other Events and Regulation FD Disclosure

On September 19, 2003, IntraBiotics Pharmaceuticals, Inc. issued a press release entitled, IntraBiotics Reaches Special Protocol Assessment (SPA) Agreement with FDA . This press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 7. Financial Statements, *Pro Forma Financial Information* and Exhibits

(c) Exhibits.

99.1 Press Release, dated September 19, 2003, entitled IntraBiotics Reaches Special Protocol Assessment (SPA) Agreement with FDA.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: September 23, 2003

INTRABIOTICS PHARMACEUTICALS, INC.

By: /s/ Eric Bjerkholt

Eric H. Bjerkholt
Sr. Vice President and
Chief Financial Officer

Table of Contents

INDEX TO EXHIBITS

99.1 Press Release, dated September 19, 2003, entitled IntraBiotics Reaches Special Protocol Assessment (SPA) Agreement with FDA.